AIM: Overexpression of tumor protein p53-induced nuclear protein 1 (TP53INP1) induces G1 cell cycle arrest and increases p53-mediated apoptosis. To clarify the clinical importance of TP53INP1, we analyzed TP53INP1 and p53 expression in gastric cancer. METHODS: TP53INP1 and p53 expression were examined using immunohistochemistry in 142 cases of gastric cancer. The apoptosis of gastric cancer cells was analyzed using the TUNEL method. The relationship between the expression of TP53INP1 and clinicopathological factors was statistically analyzed. RESULTS: TP53INP1 was expressed in 98% (139/142 cases) of non-cancerous gastric tissues and was down-expressed in 64% (91/142 cases) of gastric cancer lesions from the same patients. TP53INP1 expression was significantly decreased (43.9%) in poorly differentiated adenocarcinoma compared with well or moderately differentiated adenocarcinoma (81.6%). Cancers invading the submucosa or deeper showed lower positively (59.1%) compared with mucosal cancers (85.2%). Decrease or loss of TP53INP1 expression was significantly correlated with lymphatic invasion (54.3% vs 82.0% without lymphatic invasion) and node-positive patients (31.3% vs 68.3% in node-negative patients). P53 was expressed in 68 (47.9%) patients of gastric cancer, whereas it was absent in normal gastric tissues. A significant association was also observed between TP53INP1 status and the level of apoptosis in tumor cells: the apoptotic index in TP53INP1-positive tissues was significantly higher than that in TP53INP1-negative portions. Finally, when survival data were analyzed, loss of TP53INP1 expression had a significant effect in predicting a poor prognosis (P=0.0006). CONCLUSION: TP53INP1-positive rate decreases with the progression of gastric cancer. TP53INP1 protein negativity is significantly associated with aggressive pathological phenotypes of gastric cancer. TP53INP1 is related to the apoptosis of gastric cancer cells. The decreased expression of the TP53INP1 protein may reflect the malignant grade of gastric cancer and is regarded as an adverse prognostic factor.
AIM: Overexpression of tumor protein p53-induced nuclear protein 1 (TP53INP1) induces G1 cell cycle arrest and increases p53-mediated apoptosis. To clarify the clinical importance of TP53INP1, we analyzed TP53INP1 and p53 expression in gastric cancer. METHODS:TP53INP1 and p53 expression were examined using immunohistochemistry in 142 cases of gastric cancer. The apoptosis of gastric cancer cells was analyzed using the TUNEL method. The relationship between the expression of TP53INP1 and clinicopathological factors was statistically analyzed. RESULTS:TP53INP1 was expressed in 98% (139/142 cases) of non-cancerous gastric tissues and was down-expressed in 64% (91/142 cases) of gastric cancer lesions from the same patients. TP53INP1 expression was significantly decreased (43.9%) in poorly differentiated adenocarcinoma compared with well or moderately differentiated adenocarcinoma (81.6%). Cancers invading the submucosa or deeper showed lower positively (59.1%) compared with mucosal cancers (85.2%). Decrease or loss of TP53INP1 expression was significantly correlated with lymphatic invasion (54.3% vs 82.0% without lymphatic invasion) and node-positive patients (31.3% vs 68.3% in node-negative patients). P53 was expressed in 68 (47.9%) patients of gastric cancer, whereas it was absent in normal gastric tissues. A significant association was also observed between TP53INP1 status and the level of apoptosis in tumor cells: the apoptotic index in TP53INP1-positive tissues was significantly higher than that in TP53INP1-negative portions. Finally, when survival data were analyzed, loss of TP53INP1 expression had a significant effect in predicting a poor prognosis (P=0.0006). CONCLUSION:TP53INP1-positive rate decreases with the progression of gastric cancer. TP53INP1 protein negativity is significantly associated with aggressive pathological phenotypes of gastric cancer. TP53INP1 is related to the apoptosis of gastric cancer cells. The decreased expression of the TP53INP1 protein may reflect the malignant grade of gastric cancer and is regarded as an adverse prognostic factor.
Authors: A Zur Hausen; B P van Rees; J van Beek; M E Craanen; E Bloemena; G J A Offerhaus; C J L M Meijer; A J C van den Brule Journal: J Clin Pathol Date: 2004-05 Impact factor: 3.411
Authors: Richard Tomasini; Amina Azizi Samir; Alice Carrier; Daniel Isnardon; Barbara Cecchinelli; Silvia Soddu; Bernard Malissen; Jean-Charles Dagorn; Juan L Iovanna; Nelson J Dusetti Journal: J Biol Chem Date: 2003-07-07 Impact factor: 5.157
Authors: Christoph Jung; Monica Motwani; Jeremy Kortmansky; Francis M Sirotnak; Yuhong She; Mithat Gonen; Adriana Haimovitz-Friedman; Gary K Schwartz Journal: Clin Cancer Res Date: 2003-12-01 Impact factor: 12.531
Authors: Richard Tomasini; Amina Azizi Samir; Marie-Josèphe Pebusque; Ezequiel L Calvo; Serena Totaro; Jean Charles Dagorn; Nelson J Dusetti; Juan L Iovanna Journal: Eur J Cell Biol Date: 2002-05 Impact factor: 4.492
Authors: Houda Saadi; Marion Seillier; Maria José Sandi; Sylvain Peuget; Christine Kellenberger; Gwenaëlle Gravis; Nelson J Dusetti; Juan L Iovanna; Palma Rocchi; Mohamed Amri; Alice Carrier Journal: Results Immunol Date: 2013-05-28
Authors: Tatiana S Kalinina; Vladislav V Kononchuk; Vladimir Y Ovchinnikov; Mikhail D Chanyshev; Lyudmila F Gulyaeva Journal: Mol Biol Rep Date: 2018-11-12 Impact factor: 2.316
Authors: A C West; K Tang; H Tye; L Yu; N Deng; M Najdovska; S J Lin; J J Balic; E Okochi-Takada; P McGuirk; B Keogh; W McCormack; P S Bhathal; M Reilly; M Oshima; T Ushijima; P Tan; B J Jenkins Journal: Oncogene Date: 2017-05-08 Impact factor: 9.867
Authors: D Taïeb; S Giusiano; F Sebag; M Marcy; C de Micco; F F Palazzo; N J Dusetti; J L Iovanna; J F Henry; S Garcia; Colette Taranger-Charpin Journal: World J Surg Date: 2010-04 Impact factor: 3.352